Effect of Ramipril vs Amlodipine on Renal Outcomes in Hypertensive Nephrosclerosis: A Randomized Controlled Trial
Article Abstract:
The ACE inhibitor ramipril may slow the progression of kidney disease in African-Americans who have hypertension. This was the conclusion of a study of 1,094 African-Americans who had hypertensive kidney disease.
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2001
User Contributions:
Comment about this article or add new information about this topic:
Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial: racial and treatment effects
Article Abstract:
African American patients with hypertension may be more likely to develop impaired kidney function than are members of other ethnic groups despite special treatment for the condition. Among 5,524 men with mild to moderate high blood pressure, 2,758 received special treatment for high blood pressure and 2,766 received the usual care. Control of blood pressure was approximately the same in both treatment groups and among patients from different ethnic groups, but black patients were more likely to develop impaired kidney function than non-black patients. Patients with both increased systolic and diastolic blood pressure and older patients were also more likely to develop impaired kidney function. Decreased diastolic blood pressure was associated with a lower chance of kidney disorders among the non-black patients. Treatment to maintain a decreased diastolic blood pressure did not affect the risk of developing impaired kidney function among the black patients.
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 1992
User Contributions:
Comment about this article or add new information about this topic:
Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: A randomized controlled trial
Article Abstract:
The study comparing the effects of beta-blockers with different pharmacological profiles on glycemic and metabolic control in participants with diabetes mellitus (DM) and hypertension receiving renin-angiotensin system (RAS) blockade, in the context of cardiovascular risk factors is presented. It is concluded that the use of carvedilol in the presence of RAS blockade did not affect glycemic control and improved some components of the metabolic syndrome relative to metoprolol in participants with DM and hypertension.
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Leukocyte-Reduced Red Blood Cell Transfusions in Patients With Anemia and Human Immunodeficiency Virus Infection: A Randomized Controlled Trial
- Abstracts: Effects of Atorvastatin of Early Recurrent Ischemic Events in Acute Coronary Syndromes: A Randomized Controlled Trial
- Abstracts: Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With Raloxifene: Results From a 3-Year Randomized Clinical Trial
- Abstracts: Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. Effect of carvedilol on survival in severe chronic heart failure
- Abstracts: Assisted suicide and alternatives in amyotrophic lateral sclerosis. Amyotrophic lateral sclerosis